Imaradenant (AZD4635) - 98%, high purity , Adenosine A2a receptor antagonist, CAS No.1321514-06-0, Adenosine A2a receptor antagonist

Item Number

I414133

Grouped product items
SKU	Size	Availability	Price
I414133-5mg	5mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$69.90
I414133-10mg	10mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$114.90
I414133-25mg	25mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$194.90
I414133-50mg	50mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$289.90
I414133-100mg	100mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$449.90

Adenosine Receptor Antagonists

View related series

Basic Description

Synonyms	C72299 \| S8720 \| AZD4635 (HTL1071) \| HTL1071 \| HTL-1071 \| 1321514-06-0 \| AKOS037515559 \| IMARADENANT [WHO-DD] \| 5-(4-fluorophenyl)-6-(2-chloro-6-methyl-pyridin-4-yl)-1,2,4-triazin-3-amine \| CS-0022379 \| NCWQLHHDGDXIJN-UHFFFAOYSA-N \| HY-101980 \| BS-15183 \|
Specifications & Purity	Moligand™, ≥98%
Biochemical and Physiological Mechanisms	Imaradenant (AZD4635, HTL1071) is an oral A2AR antagonist that binds to human A2AR with a Ki of 1.7 nM and with > 30-fold selectivity over other adenosine receptors.
Storage Temp	Store at -20°C
Shipped In	Ice chest + Ice pads
Grade	Moligand™
Action Type	ANTAGONIST
Mechanism of action	Adenosine A2a receptor antagonist
Product Description	Information Imaradenant (AZD4635) Imaradenant (AZD4635, HTL1071) is an oral A2AR antagonist that binds to human A2AR with a Ki of 1.7 nM and with > 30-fold selectivity over other adenosine receptors. Targets A2AR (Cell-free) 1.7 nM(Ki) In vitro In CHO cells stably expressing human A2AR, the IC50s of AZD4635 for inhibition of cAMP production are 0.79, 10.0 and 142.9 nM in the presense of 0.1, 1 and 10 μM adenosine, respectively. In vivo Blockade of A2AR signaling with AZD4635 could reduce tumor burden and enhance antitumor immunity.

Names and Identifiers

IUPAC Name	6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine
INCHI	InChI=1S/C15H11ClFN5/c1-8-6-10(7-12(16)19-8)14-13(20-15(18)22-21-14)9-2-4-11(17)5-3-9/h2-7H,1H3,(H2,18,20,22)
InChi Key	NCWQLHHDGDXIJN-UHFFFAOYSA-N
Canonical SMILES	CC1=CC(=CC(=N1)Cl)C2=C(N=C(N=N2)N)C3=CC=C(C=C3)F
Isomeric SMILES	CC1=CC(=CC(=N1)Cl)C2=C(N=C(N=N2)N)C3=CC=C(C=C3)F
PubChem CID	86676119
Molecular Weight	315.73

Certificates（CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):

Analytical Chart:

Find and download the COA for your product by matching the lot number on the packaging.

8 results found

Lot Number	Certificate Type	Date	Item
L2313374	Certificate of Analysis	Nov 27, 2023	I414133
L2314344	Certificate of Analysis	Nov 27, 2023	I414133
L2314345	Certificate of Analysis	Nov 27, 2023	I414133
L2314346	Certificate of Analysis	Nov 27, 2023	I414133
L2314347	Certificate of Analysis	Nov 27, 2023	I414133
L2314348	Certificate of Analysis	Nov 27, 2023	I414133
L2314373	Certificate of Analysis	Nov 27, 2023	I414133
L2314375	Certificate of Analysis	Nov 27, 2023	I414133

References

1. Borodovsky A, Barbon CM, Wang Y, Ye M, Prickett L, Chandra D, Shaw J, Deng N, Sachsenmeier K, Clarke JD et al.. (2020) Small molecule AZD4635 inhibitor of A 2A R signaling rescues immune cell function including CD103 + dendritic cells enhancing anti-tumor immunity. J Immunother Cancer, 8 (2): (e000417). [PMID:32727810] [10.1136/jitc-2019-000417]
2. A-González N, Castrillo A. (2011) Liver X receptors as regulators of macrophage inflammatory and metabolic pathways.. Biochim Biophys Acta, 1812 (8): (982-94). [PMID:21193033] [10.1021/op500134e]

Solution Calculators

Determine the necessary mass, volume, or concentration for preparing a solution.

Determine the dilution needed to prepare a stock solution.

Basic Description